Format

Send to

Choose Destination
Ophthalmology. 2019 Jun;126(6):792-800. doi: 10.1016/j.ophtha.2019.01.024. Epub 2019 Jan 28.

A Clinical Phase II Study to Assess Efficacy, Safety, and Tolerability of Waterfree Cyclosporine Formulation for Treatment of Dry Eye Disease.

Author information

1
Eye Research Foundation, Newport Beach, California.
2
Andover Eye Associates, Andover, Massachusetts.
3
MedRACS Clinical Research, LLC, Quincy, Massachusetts.
4
Central Maine Eye Care, Lewiston, Maine.
5
Massachusetts Eye and Ear Infirmary / Harvard Medical School, Boston, Massachusetts.
6
BAST Modelling & Simulation Consultancy Service, Heidelberg, Germany.
7
Clinical and Regulatory Affairs Consultancy Services (CaRACS), Berlin, Germany.
8
Ora Inc, Andover, Massachusetts.
9
Department of Ophthalmology, Medical Faculty, University of Cologne, Cologne, Germany.
10
Novaliq GmbH, Heidelberg, Germany. Electronic address: skroesser@novaliq.com.

Abstract

PURPOSE:

To compare the efficacy, safety, and tolerability of waterfree cyclosporine formulation (CyclASol) at 2 concentrations (0.1% and 0.05% of cyclosporine [CsA]) to vehicle when applied twice daily for 16 weeks in patients with dry eye disease (DED). An open-label Restasis (Allergan, Irvine, CA) arm was included to allow a direct comparison with an approved therapy.

DESIGN:

An exploratory phase II, multicenter, randomized, vehicle-controlled clinical trial, double-masked between CyclASol and vehicle with an open-label comparator.

PARTICIPANTS:

Two hundred and seven eligible patients with a history of dry eye disease were randomized 1:1:1:1 to 1 of 4 treatment arms (CyclASol 0.05%, n = 51; CyclASol 0.1%, n = 51; vehicle, n = 52, and Restasis, n = 53).

METHODS:

After a 2-week run-in period with twice-daily dosing of Systane Balance (Alcon, Fort Worth, TX), patients were randomized to the respective treatment arm and dosed twice daily for 16 weeks.

MAIN OUTCOME MEASURES:

The study was set up to explore efficacy on a number of sign and symptom end points including total and subregion corneal fluorescein staining, conjunctival staining, visual analog scale (VAS) for dry eye symptoms VAS severity, and Ocular Surface Disease Index (OSDI) questionnaire.

RESULTS:

CyclASol showed a consistent reduction in corneal and conjunctival staining compared with both vehicle and Restasis over the 16-week treatment period, with an early onset of effect (at day 14). A mixed-effects model-based approach demonstrated that the CyclASol drug effect was statistically significant over vehicle (total corneal staining P < 0.1, central corneal staining P < 0.001, conjunctival staining P < 0.01). This model-based analysis suggests a significant CyclASol effect for OSDI as symptom parameter (P < 0.01). The numbers of ocular adverse events were low in all treatment groups.

CONCLUSIONS:

CyclASol showed efficacy, safety, and tolerability at 2 concentrations in moderate-to-severe DED. In a direct head-to-head against open-label Restasis, CyclASol was found to have an earlier onset of action, as early as after 2 weeks of treatment, in relieving the signs of DED, as measured by corneal and conjunctival staining. The central region of the cornea, an important area for visual function in dry eye sufferers, was shown to have the most benefit from treatment. Excellent safety, tolerability, and comfort profile supports this new CsA formulation as having a positive benefit-to-risk ratio.

TRIAL REGISTRATION:

ClinicalTrials.gov NCT02617667.

PMID:
30703441
DOI:
10.1016/j.ophtha.2019.01.024
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center